Media Room
latest news
New brochure to discover the AMR Industry Alliance in 2 minutes
Representing more than 100 biotechnology, diagnostics, generics and research-based pharmaceutical companies and associations, the AMR Industry Alliance is one of the largest private sector coalitions...
Read more
AMR Industry Alliance Round-Up, Issue No.1, June 2019
This is the first issue of "Alliance Round-Up" written for the more than 100 biotech, diagnostic, generic and pharma companies who are members of the AMR Industry Alliance, as well as people...
Read more
The largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all stakeholders
The largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all st...
Read morefrom the blog
Overcoming Access Barriers to Antibiotics
Somewhat perversely, antibiotic overuse exists side-by-side with lack of access to such medicines in today’s world. While we are aware of the consequences of drug-resistant bacterial infections, it...
Read more
Creating new antimicrobial drugs will require governments working with industry
As the number of infections resistant to antimicrobial drugs continues to rise around the world, and with it their huge human and financial toll, we urgently need new ways to preserve the effectivenes...
Read more
By 2050, superbugs may cost the economy $100 trillion
This oped was first published in the Antimicrobial Resistance campaign in the Guardian on 12 November 2018. ANTIBIOTIC RESISTANCE Evidence suggests superbugs could cost the global economy up to 3....
Read morein the press
Pharmaceuticals in the Environment
This article was published on PharmTech on 2 August, 2018 (Pharmaceutical Technology, Volume 42, Issue 8). Content by Sean Milmo. "An Antimicrobial Resistance (AMR) Industry Allian...
Read more
Antimicrobial resistance and vaccines – Life science industry makes the link and drives progress
This Q&A was first published on PharmExec on 20 April, 2018. Interview by Julian Upton. 1. When trying to reduce antimicrobial resistance, how can vaccines help? Vaccines are critical and po...
Read more
NZZ – We need a sustainable business model
This interview was first published on NZZ on 24 February 2018. Interview by Birgit Voigt. NZZ on Sunday: Why is the pharmaceutical industry not developing more new antibiotics? Thomas Cueni: Today...
Read more